- Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needs
- Tryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indications
- The company expects to begin manufacturing its initial oral psilocybin formulation in September 2021
- Tryp’s scientific and executive team has decades of experience in large pharma, emerging pharma, drug approvals, psychedelics and capital markets to draw on in developing its product
- The company is also working with pharmaceutical partners whose diversity of experience will provide support for Tryp’s path to oral psilocybin development
Bio-pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is working to develop novel solutions for diseases that otherwise have unmet medical needs, focusing its flagship initiative on fibromyalgia and binge eating conditions with a team of experienced professionals and skilled partners set to accelerate the development of its products.
Tryp’s TRP-8802 synthetic psilocybin Active Pharmaceutical Ingredient (“API”) will soon be used to initiate Phase 2a clinical trials at the University of Florida for efficacy in treating specific neurologic causes of eating disorders — primarily hyperphagia, which is a condition in which the patients never feel full, so they are continually wanting to eat.
Tryp’s trademarked Psilocybin-for-Neuropsychiatric Disorders (“PFN”)(TM) program is also focused on the chronic pain associated with fibromyalgia. The novelty of developing psychedelic substances for medicinal purposes requires that the program be led by individuals with significant drug development experience.
Tryp’s team of executives and advisors made up of deep understanding gained through their work in large pharma, emerging pharma, drug approvals, psychedelics and capital markets, as noted in a recent NetworkNewsAudio broadcast (https://ibn.fm/P2SXq).
The company’s executive team boasts decades working in leadership positions with Genzyme, Unigene Laboratories, Syntex, Nventa Biopharmaceuticals, Dow Chemical, ImmunoPrecise, Jubilant, and other organizations.
Tryp’s COO, Tom D’Orazio, has helped shepherd two cancer drugs through the approval process with Health Canada, and the company’s Vice President, Manufacturing, Larry Norder, worked with early-stage research, preclinical and clinical developments for the blockbuster nonsteroidal anti-inflammatory drug Naproxen, the generic name for pain-reliever Aleve.
Pediatric eating disorders expert Jennifer Miller, M.D. of the University of Florida is directing the investigation of Tryp’s TRP-8802 psilocybin product. As director of University of Florida Health’s Prader-Willi Syndrome (“PWS”) Program and professor in the Division of Pediatric Endocrinology at the University of Florida Department of Pediatrics, she follows one of the largest cohorts of PWS patients in the world.
PWS is a genetic disorder involving chromosomal loss or alteration whose patients experience difficulties adapting to changes, uncontrolled mood, insatiable hunger — known clinically as hyperphagia — and food impulsivity. This frequently leads to the negative health effects associated with obesity, although researchers have noted that the lockdowns resulting from the COVID pandemic have led to significant weight loss in a large percentage of patients (https://ibn.fm/F3R2x).
Pharmaceutical research companies are partnering with Tryp to provide support services for the development of its synthetic psilocybin product. Psychedelic therapy educational platform Fluence will provide design and training for the psychotherapeutic portion of Tryp’s upcoming clinical trials (https://ibn.fm/qxc92). Global novel pharmaceutical product contract research organization (“CRO”) Clinlogix will provide its support services for clinical trials (https://ibn.fm/8b5kY), and Tryp announced on May 25 that global pharmaceutical contract development and manufacturing organization Alcami Corporation will support development of proprietary oral formulations for TRP-8802, which is manufactured by Albany Molecular Research, Inc. (“AMRI”) (https://ibn.fm/TlTXi).
Tryp expects to manufacture its initial batch of cGMP psilocybin API in September 2021, according to the company’s latest news release. Alcami and Tryp will then work together to develop the analytical methods and the final formulation for the oral psilocybin product.
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
